A New Assay Based on Thrombin Generation Inhibition to Detect Both Protein C and Protein S Deficiencies in Plasma

Summary

Activated protein C reduces thrombin generation by inactivating factors V and VIII in the presence of protein S. This prompted us to develop an assay which would allow specific exploration of this reaction. The total amount of thrombin formed in plasma after activation by tissue factor and phospholipids was reduced by adding thrombomodulin. This addition allowed protein C to be activated by endogenous thrombin. The inhibition of thrombin generation (ITG) due to protein C activation could be measured by comparing thrombin formation in the presence and in the absence of thrombomodulin. ITG increased with both protein C and protein S concentrations. Normal values of ITG expressed as a percentage were between 40 and 65% and were not influenced by age or sex. ITG increased in patients under heparin therapy, decreased in patients under oral anticoagulant therapy and was decreased in women using oral contraceptives. This method could be used for screening patients for protein C and protein S deficiencies.

• References

• 1 Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEBJ 1992; 6: 2561-7
• 2 Dahlback B, Carlsson M, Svenson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8
• 3 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3
• 4 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-8
• 5 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.. N Engl J Med 1984; 311: 1525-8
• 6 Francis RB, Patch MJ. A functional assay for protein C in human plasma. Thromb Res 1983; 32: 605-13
• 7 Vigano-D’Angelo S, Comp PC, Esmon CT, D’Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-25
• 8 Martinoli JL, Stocker K. Fast functional protein C assay using Protact, a novel protein C activator. Thromb Res 1986; 43: 253-64
• 9 Guglielmone HA, Vides MA. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemostas 1992; 67: 46-9
• 10 Wolf M, Boyer-Neumann C, Martinoli JL, Leroy-Matheron C, Amiral J, Meyer D, Larrieu MJ. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemostas 1989; 62: 1144-5
• 11 Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotto E, Manucci PM. A prothrombin time-based functional assay of protein S. Thromb Res 1990; 60: 19-32
• 12 Hemker HC, Willems GM, Beguin SA. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 13 Preissner KT, Koyama T, Muller D, Tschopp J, Muller-Berghaus G. Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions. J Biol Chem 1990; 265: 4915-22
• 14 Aiach M, Francois D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M, Fiessenger JN. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. Br J Haematol 1987; 66: 515-22
• 15 Beguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombmase activity and the standardisation of heparin activity. Thromb Haemostas 1992; 68: 136-42
• 16 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 17 Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. In press
• 18 Hoogendoorn H, Toh CH, Nesheim ME, Giles AR. α₂ Macroglobulin binds and inhibits activated protein C. Blood 1991; 78: 2283-90
• 19 Van WijngardenA, Van den Kesselaar AMPH, Rertina RM. Thrombomodulin activity in commercial thromboplastin preparation. Thromb Res 1986; 43: 265-74
• 20 Bourm MC, Lindahl U. Functional role of polysaccharide component of rabbit thrombomodulin proteoglycan. Effects on inactivation of thrombin by anti-thrombin, cleavage of fibrinogen by thrombin and thrombin-catalysed activation of factor V. Biochem J 1990; 270: 419-25
• 21 Machovich R, Bourin MC, Bombled J, Barbier D, Boffa MC. Effect of thrombomodulin on thrombin activities. Thromb Haemostas 1983; 50: 351
• 22 Andrew M, Vcgh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 8: 1998-2005
• 23 Oosting JD, Derksen RHWM, Bobbink IWG, Hackcng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explication for their pathogenic mechanism?. Blood 1993; 81: 2618-25
• 24 Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-63
• 25 Bertina RM, Broekmans AW, Kroemmeuhaevan ESC, Van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemostas 1984; 51: 1-5
• 26 Miletich JP. Laboratory diagnosis of protein C deficiency. Sem Thromb Hemostas 1990; 16: 169-76
• 27 Comp PC. Laboratory evaluation of protein S status. Sem Thromb Hemostas 1990; 16: 177-81
• 28 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8